Abingdon HealthABDXF +11.07%49 PS Ratio is 4.09 as of Jun. 28, 2026, which is 27% below its 10-year median of 5.63. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.24 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Abingdon Health ranks worse than 61.69% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Abingdon Health's share price is $0.135.
Abingdon Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.03. Hence, Abingdon Health's PS Ratio for today is 4.09.
The historical rank and industry rank for Abingdon Health's PS Ratio or its related term are showing as below:
ABDXF'
s PS Ratio Range Over the Past 10 Years
Min: 1.88 Med: 5.63 Max: 19.12
Current: 4.1
During the past 8 years, Abingdon Health's highest PS Ratio was 19.12. The lowest was 1.88. And the median was 5.63.
ABDXF's PS Ratio is ranked worse than 61.69% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.78
vs ABDXF: 4.10
Abingdon Health PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Abingdon Health was 19.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 32.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -16.90% per year.
During the past 8 years, Abingdon Health's highest 3-Year average Revenue per Share Growth Rate was 32.00% per year. The lowest was -38.20% per year. And the median was -24.20% per year.
Back to Basics: PS Ratio
Abingdon Health (OTCPK:ABDXF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Abingdon Health PS Ratio Related Terms
Abingdon Health PS Ratio Historical Data
* Premium members only.
The historical data trend for Abingdon Health's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Abingdon Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's PS Ratio distribution charts can be found below:
* The bar in red indicates where Abingdon Health's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Abingdon Health's Share Price of today is $0.135.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abingdon Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Abingdon Health (ABDXF) has a PS Ratio of 4.09 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Abingdon Health and its competitors. This is 27% below median its historical median of 5.63. Over the past decade, Abingdon Health's PS Ratio has ranged from 1.88 to 19.12. According to the industry distribution chart, Abingdon Health ranks #124 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 61.7%.
Is Abingdon Health's PS Ratio too high?
Abingdon Health's current PS Ratio of 4.09 is 27% below median its 10-year median of 5.63. Over the past 10 years, this metric has ranged from a low of 1.88 to a high of 19.12. The Medical Diagnostics & Research industry median PS Ratio is 2.78. Abingdon Health's value of 4.09 is 47.1% above this industry median. Based on the distribution chart, Abingdon Health ranks #124 out of 201 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #124 out of 201 companies for PS Ratio. This places Abingdon Health in the lower half of its industry. The industry median PS Ratio is 2.78. Abingdon Health's value of 4.09 is 47.1% above this benchmark. Historically, Abingdon Health's own PS Ratio has ranged from 1.88 to 19.12 over the past decade. While the company's 10-year median is 5.63 vs. the industry median of 2.78, Abingdon Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.78, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abingdon Health's current PS Ratio of 4.09 is 47.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Abingdon Health and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current PS Ratio is 4.09, which is 27% below median its own 10-year median of 5.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.24, compared to a current price of $0.14 — trading 43.8% below its estimated fair value. The current PS Ratio is 4.09, which is 27% below median its 10-year median of 5.63 and 47.1% above the Medical Diagnostics & Research industry median of 2.78. Abingdon Health's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current PS Ratio is 4.09 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.14 is trading 43.8% below its estimated GF Value™ of $0.24.
GuruFocus considers Abingdon Health to be Possible Value Trap.
Key valuation signals for ABDXF:
PS Ratio: 4.09 (27% below median its 10-year median of 5.63)
GF Value™: $0.24 vs. price of $0.14 (43.8% below fair value)
Industry Position: 47.1% above the Medical Diagnostics & Research median (#124 of 201)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
